Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Domatinostat - 4SC

Next Previous
Drug Profile

Domatinostat - 4SC

Alternative Names: 4SC-202

Latest Information Update: 13 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nycomed
  • Developer 4SC; Netherlands Cancer Institute; Vuja De Sciences
  • Class Antineoplastics; Benzamides; Pyrazoles; Pyrroles; Small molecules; Sulfones
  • Mechanism of Action BRD4 protein modulators; HDAC1 protein inhibitors; HDAC2 protein inhibitors; HDAC3 protein inhibitors; Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Osteosarcoma; Sarcoma
  • Discontinued Bladder cancer; Cancer; Colorectal cancer; Gastrointestinal cancer; Haematological malignancies; Malignant melanoma; Merkel cell carcinoma; Oesophageal cancer; Pancreatic cancer; Small cell lung cancer; Triple negative breast cancer

Most Recent Events

  • 30 Dec 2024 The Netherlands Cancer Institute completes a phase I trial in Bladder cancer (Combination therapy, Inoperable/Unresectable, Neoadjuvant therapy, Late-stage disease) in Netherlands (IV) (NCT04871594)
  • 24 Oct 2024 Preclinical trials in Osteosarcoma in USA (PO) prior to October 2024 (Vuja De Sciences Pipeline, October 2024)
  • 24 Oct 2024 Preclinical trials in Sarcoma in USA (PO) prior to October 2024 (Vuja De Sciences Pipeline, October 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top